{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:23Z","timestamp":1779951743391,"version":"3.53.1"},"reference-count":177,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>B-cell lymphomas (BCLs) are a heterogeneous group of blood cancers whose treatment has been significantly transformed by immunotherapy. The use of the anti-CD20 monoclonal antibody rituximab, combined with chemotherapy (R-CHOP), has markedly improved patient outcomes. However, some subtypes, particularly Diffuse Large B-Cell Lymphoma (DLBCL), remain challenging to treat due to frequent relapses and\/or early resistance to therapy. Standard frontline immunochemotherapy is successful in about 60% of DLBCL cases, whereas 30-40% experience relapse or refractory disease, thus highlighting the urgent need for more effective therapeutic strategies. More recently, advanced immunotherapies have been investigated, relying on the use of innovative bi- and trispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. Furthermore, immune effector cell-based therapies, such as CAR-T and CAR-NK cells, have been developed. Among these, CAR-T cell therapy targeting CD19 achieved high response rates in patients with relapsed or refractory DLBCL, emerging as new pivotal therapeutic option. In this narrative review, we provide an overview of current immunotherapy treatments for DLBCL, including underlying mechanisms, clinical outcomes, and safety profiles.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1835301","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:15:34Z","timestamp":1779948934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna","family":"Aureli","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Institute of Translational Pharmacology, National Research Council (CNR)","place":["Rome,, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lanzilli","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Institute of Translational Pharmacology, National Research Council (CNR)","place":["Rome,, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano Vito","family":"Boccadamo Pompili","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Institute of Translational Pharmacology, National Research Council (CNR)","place":["Rome,, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Cesare","family":"Spagnoli","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Institute of Translational Pharmacology, National Research Council (CNR)","place":["Rome,, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sconocchia","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Institute of Translational Pharmacology, National Research Council (CNR)","place":["Rome,, Italy"]},{"name":"Saint Camillus, International Medical University (UNICAMILLUS)","place":["Rome,, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Caratelli","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Institute of Translational Pharmacology, National Research Council (CNR)","place":["Rome,, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Prim Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2008.03.005","article-title":"Overview of lymphoma diagnosis and management","volume":"46","author":"Matasar","year":"2008","journal-title":"Radiol Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminhematol.2015.01.006","article-title":"The histological classification of diffuse large B-cell lymphomas","volume":"52","author":"Xie","year":"2015","journal-title":"Semin Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.002","article-title":"DLBCL arising from indolent lymphomas: How are they different","volume":"60","author":"Parry","year":"2023","journal-title":"Semin Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2119","article-title":"Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations","volume":"101","author":"Martinez-Climent","year":"2003","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-691345","article-title":"Can histologic transformation of follicular lymphoma be predicted and prevented","volume":"130","author":"Kridel","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05880-z","article-title":"Advances in biology, diagnosis and treatment of DLBCL","volume":"103","author":"Shi","year":"2024","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: Definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13276","article-title":"A clinician\u2019s guide to double hit lymphomas","volume":"168","author":"Cheah","year":"2015","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00970-z","article-title":"Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands","volume":"14","author":"Pennings","year":"2024","journal-title":"Blood Cancer J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v92.6.1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1200\/JCO.2021.39.15_suppl.7513","article-title":"Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL)","volume":"39","author":"Duell","year":"2021","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-140314","article-title":"Long-term subgroup analyses from L-Mind, a phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"136","author":"Maddocks","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03169-9","article-title":"Loncastuximab tesirine versus polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL after \u2265 2 lines of therapy: matching-adjusted indirect comparison","volume":"42","author":"Wilson","year":"2025","journal-title":"Adv Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017734","article-title":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial","volume":"141","author":"Song","year":"2023","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3164_413","article-title":"Combination of imvotamab and loncastuximab tesirine shows enhanced anti-tumor activity in a preclinical model of non-Hodgkin\u2019s lymphoma","volume":"41","author":"Logronio","year":"2023","journal-title":"Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2023-180333","article-title":"Mitigating the risk of cytokine release syndrome (CRS): preliminary results from a DLBCL cohort of Epcore NHL-1","volume":"142","author":"Vose","year":"2023","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1200\/JCO.2024.42.16_suppl.7039","article-title":"Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: subcutaneous epcoritamab monotherapy in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL)","volume":"42","author":"Karimi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3153","article-title":"CAR T-cell therapy in large B cell lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1207764","article-title":"Ofatumumab monotherapy in relapsed\/refractory diffuse large B-cell non-Hodgkin lymphoma","volume":"58","author":"Galanina","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1634\/theoncologist.2019-0286","article-title":"Phase II study of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy","volume":"24","author":"Flinn","year":"2019","journal-title":"Oncologist"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.198","article-title":"Efficacy of brentuximab vedotin in relapsed or refractory high-CD30\u2013expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase II trial","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat Off J Korean Cancer Assoc"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1718103","article-title":"Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis","volume":"19","author":"Gao","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01601.x","article-title":"Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy","volume":"101","author":"Ogura","year":"2010","journal-title":"Cancer Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2022-168904","article-title":"PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell Malignancies","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137328","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: long term follow up and analysis of the mechanism of Pdl-1 tumor expression","volume":"136","author":"Smith","year":"2020","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1376490","article-title":"Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure","volume":"14","author":"Xue","year":"2024","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026401","article-title":"A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"145","author":"Yu","year":"2025","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3031.3031","article-title":"A first-in-human study of autologous T lymphocytes with antibody-dependent cell cytotoxicity (ADCC) in patients with B-cell non-Hodgkin lymphoma (NHL)","volume":"128","author":"Poon","year":"2016","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2019-123810","article-title":"A phase 1 study of ACTR087 in combination with rituximab, in subjects with relapsed or refractory CD20-positive B-cell lymphoma","volume":"134","author":"Munoz","year":"2019","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTCT.2023.10.014","article-title":"Results from a phase 1 study of ACTR707 in combination with rituximab in patients with relapsed or refractory CD20+ B cell lymphoma","volume":"30","author":"Munoz","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0099-T","article-title":"Gene-modified human \u03b1\/\u03b2-T cells expressing a chimeric CD16-CD3\u03b6 receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy","volume":"2","author":"Ochi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/0008-5472.can-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antiboby-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.10.014","article-title":"T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G\u2013opsonized target cells","volume":"18","author":"D\u2019Aloia","year":"2015","journal-title":"Cytotherapy"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2714","article-title":"Development of engineered t cells expressing a chimeric CD16-CD3\u03b6 receptor to improve the clinical efficacy of mogamulizumab therapy against adult T-cell leukemia","volume":"22","author":"Tanaka","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32663","article-title":"In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab","volume":"146","author":"Caratelli","year":"2020","journal-title":"Int J Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32618","article-title":"CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab","volume":"146","author":"Arriga","year":"2020","journal-title":"Int J Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s0955-0674(03)00106-6","article-title":"Targeting tumor cells","volume":"15","author":"Houshmand","year":"2003","journal-title":"Curr Opin Cell Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1995.4.377","article-title":"Alternative triggering molecules and single chain bispecific antibodies","volume":"4","author":"Segal","year":"1995","journal-title":"J Hematother"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.810737","article-title":"Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome","volume":"55","author":"Boslooper","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0019","article-title":"Treatment of aggressive non-Hodgkin\u2019s lymphoma in frail patients: cardiac comorbidities and advanced age","volume":"15","author":"Lugtenburg","year":"2019","journal-title":"Future Oncol Lond Engl"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.125344","article-title":"Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Jaeger","year":"2015","journal-title":"Haematologica"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13652","article-title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial","volume":"171","author":"Witzens-Harig","year":"2015","journal-title":"Br J Haematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.133223","article-title":"Comment on \u201cRituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Vassilakopoulos","year":"2015","journal-title":"Haematologica"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081917","article-title":"Monoclonal antibodies in the treatment of diffuse large B-cell lymphoma: Moving beyond rituximab","volume":"14","author":"Papageorgiou","year":"2022","journal-title":"Cancers"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.373","article-title":"The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients","volume":"27","author":"Kellner","year":"2013","journal-title":"Leukemia"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837457","article-title":"CD19-targeted immunotherapies for diffuse large B-cell lymphoma","volume":"13","author":"Gambella","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/onco.13789","article-title":"Identification of very low-risk subgroups of patients with primary mediastinal large B-cell lymphoma treated with R-CHOP","volume":"26","author":"Vassilakopoulos","year":"2021","journal-title":"Oncologist"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B112","article-title":"S232 inotuzumab ozogamicin plus R-CVP is A feasible and effective regimen for frontline treatment of DLBCL in patients who are unfit for R-Chop: results of A randomised phase 2 UK NCRI trial","volume":"4","author":"Phillips","year":"2020","journal-title":"Hemasphere"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1214026","article-title":"New treatment options in elderly patients with diffuse large B-cell lymphoma","volume":"13","author":"Arcari","year":"2023","journal-title":"Front Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159586","article-title":"A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma: recommended dose safety\/efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1200\/JCO.2023.41.16_suppl.7519","article-title":"Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/triple-hit lymphoma: updated EPCORE NHL-2 data","volume":"41","author":"Falchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic Malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008344","article-title":"Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma","volume":"7","author":"Younes","year":"2023","journal-title":"Blood Adv"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/hon.203_2631","article-title":"Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: Primary analysis of a phase 1b study","volume":"37","author":"Palomba","year":"2019","journal-title":"Hematol Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1200\/JCO.2021.39.15_suppl.7544","article-title":"Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin\u2019s lymphoma (R\/R iNHL): Primary analysis of a phase 2 trial from LYSA","volume":"39","author":"Herbaux","year":"2021","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1662","article-title":"Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial","volume":"6","author":"Casulo","year":"2023","journal-title":"Cancer Rep"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335424","article-title":"Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic","volume":"15","author":"Smirnov","year":"2024","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"biomark Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.008","article-title":"Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B cell lymphoma","volume":"26","author":"Oluwole","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B140","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010069","article-title":"Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed\/refractory large B-cell lymphomas: an indirect treatment comparison","volume":"63","author":"Schuster","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.019","article-title":"Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02551-z","article-title":"Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial","volume":"60","author":"Dholaria","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.04.022","article-title":"Composite mantle cell lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a clinicopathologic and molecular study","volume":"44","author":"Hoeller","year":"2013","journal-title":"Hum Pathol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell Malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1182\/blood-2024-205207","article-title":"Tandem CD19\/20 CAR-T showed durable efficacy in patients with relapsed\/refractory B-cell lymphoma: interim results from a multicenter phase I\/II trial","volume":"144","author":"Wei","year":"2024","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018598","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384039","article-title":"Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226518","article-title":"Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect in vivo","volume":"14","author":"Silvestre","year":"2023","journal-title":"Front Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030706","article-title":"You have got a fast CAR: Chimeric antigen receptor NK cells in cancer therapy","volume":"12","author":"Pfefferle","year":"2020","journal-title":"Cancers"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459818","article-title":"A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors","volume":"15","author":"Andrea","year":"2024","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.992232","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for Malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B168","article-title":"Search for: B-cell Lymphoma, CAR-NK","volume-title":"List Results","year":""},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet Lond Engl"},{"key":"B170","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat Cancer"},{"key":"B171","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00457","article-title":"FC\u03b3 chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance","volume":"8","author":"Caratelli","year":"2017","journal-title":"Front Immunol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16201","article-title":"Gene-modified NK-92MI cells expressing a chimeric CD16-BB-\u03b6 or CD64-BB-\u03b6 receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"B174","doi-asserted-by":"publisher","first-page":"112797","DOI":"10.1016\/J.CELREP.2023.112797","article-title":"T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity","volume":"42","author":"Cui","year":"2023","journal-title":"Cell Rep"},{"key":"B175","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40164-025-00601-2","article-title":"The CD64\/CD28\/CD3\u03b6 chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity","volume":"14","author":"Caratelli","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202201590","article-title":"Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment","volume":"5","author":"Sconocchia","year":"2022","journal-title":"Life Sci Alliance"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3775","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes","volume":"107","author":"Cl\u00e9menceau","year":"2006","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:15:38Z","timestamp":1779948938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":177,"alternative-id":["10.3389\/fimmu.2026.1835301"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1835301","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1835301"}}